2024
Implementing Formal Mitral Heart Team Improves Multidisciplinary Evaluation Rate and Survival of Patients With Severe Primary Mitral Regurgitation
Waldron C, Mori M, Krane M, Reinhardt S, Ahmad Y, Kaple R, Forrest J, Geirsson A. Implementing Formal Mitral Heart Team Improves Multidisciplinary Evaluation Rate and Survival of Patients With Severe Primary Mitral Regurgitation. Journal Of The American Heart Association 2024, 13: e033324. PMID: 38390804, PMCID: PMC11179864, DOI: 10.1161/jaha.123.033324.Peer-Reviewed Original ResearchSevere primary mitral regurgitationPrimary mitral regurgitationHeart failure symptomsMitral regurgitationMultidisciplinary evaluationPatient survivalHeart teamFailure symptomsSociety of Thoracic Surgeons Predicted Risk of MortalityThoracic Surgeons Predicted Risk of MortalityImprove overall patient survivalCorrection of MRAssociated with lower oddsMultidisciplinary heart teamSurvival of patientsAssociated with higher oddsOverall patient survivalProportion of patientsRetrospective cohort studyCardiac surgery servicesHistory of MIOptimal treatment decisionsPropensity-score matchingRisk of mortalityStructural cardiology
2017
OncoKB: A Precision Oncology Knowledge Base
Chakravarty D, Gao J, Phillips S, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, Hantash FM, Grupe A, Baxi SS, Callahan MK, Snyder A, Chi P, Danila D, Gounder M, Harding JJ, Hellmann MD, Iyer G, Janjigian Y, Kaley T, Levine DA, Lowery M, Omuro A, Postow MA, Rathkopf D, Shoushtari AN, Shukla N, Voss M, Paraiso E, Zehir A, Berger MF, Taylor BS, Saltz LB, Riely GJ, Ladanyi M, Hyman DM, Baselga J, Sabbatini P, Solit DB, Schultz N. OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology 2017, 2017: 1-16. PMID: 28890946, PMCID: PMC5586540, DOI: 10.1200/po.17.00011.Peer-Reviewed Original ResearchPrecision oncology knowledge baseNational Comprehensive Cancer Network guidelinesMolecular alterationsProspective clinical sequencingSomatic molecular alterationsDrug Administration labelingLevel of evidenceSpecific molecular alterationsOptimal treatment decisionsClinical support toolPrimary tumor samplesIndividual somatic mutationsEvidence-based informationExpert group recommendationsClinical benefitNetwork guidelinesActionable alterationsCancer carePotential treatment implicationsStandard treatmentTreatment decisionsPatient tumorsCancer-associated genesPredictive significanceUS Food
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply